Please use this identifier to cite or link to this item:
|Title:||Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer – a pilot study|
|Authors:||SCHEIDHAUER KLEMENS; SEIDL C.; BRUCHERTSEIFER FRANK; APOSTOLIDIS CHRISTOS; AUTENRIETH M.; KURTZ F; HORN THOMAS; SCHWAIGER M.; GSCHWEND J.E.; D’ALESSANDRIA CALO; PFOB C; SENEKOWITSCH-SCHMIDTKE R.; MORGENSTERN ALFRED|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 44 no. S2 p. S130|
|Type:||Articles in periodicals and books|
|Abstract:||Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.